Equities analysts expect that Chimerix Inc (NASDAQ:CMRX) will post earnings of ($0.49) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.43). Chimerix reported earnings of ($0.32) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 53.1%. The firm is expected to report its next earnings results on Thursday, March 1st.

On average, analysts expect that Chimerix will report full year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.56). For the next financial year, analysts expect that the company will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.12) to ($1.50). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.81 million. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%.

A number of research firms have issued reports on CMRX. ValuEngine raised shares of Chimerix from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded shares of Chimerix from a “buy” rating to a “hold” rating in a report on Monday, November 13th.

Chimerix (NASDAQ CMRX) traded up $0.02 on Tuesday, reaching $4.92. 141,000 shares of the company’s stock were exchanged, compared to its average volume of 272,989. The stock has a market cap of $229.04, a P/E ratio of -3.44 and a beta of 1.46. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.64.

In other Chimerix news, insider Linda M. Richardson sold 19,833 shares of Chimerix stock in a transaction on Friday, December 1st. The shares were sold at an average price of $4.47, for a total transaction of $88,653.51. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its stake in shares of Chimerix by 19.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock worth $9,072,000 after purchasing an additional 279,845 shares during the period. Numeric Investors LLC raised its stake in shares of Chimerix by 4.2% during the 2nd quarter. Numeric Investors LLC now owns 1,271,253 shares of the biopharmaceutical company’s stock worth $6,928,000 after purchasing an additional 51,322 shares during the period. State Street Corp raised its stake in shares of Chimerix by 7.3% during the 2nd quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock worth $4,515,000 after purchasing an additional 56,600 shares during the period. Northern Trust Corp raised its stake in shares of Chimerix by 10.4% during the 2nd quarter. Northern Trust Corp now owns 696,440 shares of the biopharmaceutical company’s stock worth $3,795,000 after purchasing an additional 65,335 shares during the period. Finally, AXA raised its stake in shares of Chimerix by 284.9% during the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock worth $1,409,000 after purchasing an additional 191,400 shares during the period. Institutional investors own 70.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Chimerix Inc (CMRX) to Post -$0.49 EPS” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/16/brokerages-expect-chimerix-inc-cmrx-to-post-0-49-eps.html.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.